Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: A systematic review

Journal of the Canadian Urological Association

Volumn 6, Issue 4, 2012, Pages 269-274

  Alhathal, Naif ^a   Elshal, Ahmed M ^a   Carrier Dr , Serge ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865838900     PISSN: 19116470     EISSN: None     Source Type: Journal    
DOI: 10.5489/cuaj.11291     Document Type: Review

References (41)

1. Mills TM, Stopper VS, Wiedmeier VT. Effects of castration and androgen replacement on the hemodynamics of penile erection in the rat. Biol Reprod 1994;51:234-238. http://dx.doi.org/10.1095/biolreprod51.2.234
2. Penson DF, Ng C, Rajfer J, et al. Adrenal control of erectile function and nitric oxide synthase in the rat penis. Endocrinology 1997;138:3925-932. http://dx.doi.org/10.1210/en.138.9.3925
3. Baba K, Yajima M, Carrier S, et al. Delayed testosterone replacement restores nitric oxide synthasecontaining nerve fibres and the erectile response in rat penis. BJU Int 2000;85:953-958. http://dx.doi.org/10.1046/j.1464-410x.2000.00598.x
4. Lugg JA, Rajfer J, Gonzalez-Cadavid N F. Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat. Endocrinology 1995;136:1495-1501. http://dx.doi.org/10.1210/en.136.4.1495
5. Park KH, Kim SW, Kim KD, et al. Effects of androgens on the expression of nitric oxide synthase mRNAs in rat corpus cavernosum. BJU Int 1999;83:327-333. http://dx.doi.org/10.1046/j.1464-410x.1999.00913.x
6. Morelli, A., Filippi, S., Mancina, R., Luconi, M., Vignozzi, L., Marini, M., et al. (2004). Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology, 145(5), 2253-2263. http://dx.doi.org/10.1210/en.2003-1699
7. Traish AM, Munarriz R, O'Connell L, et al. Effects of medical or surgical castration on erectile function in an animal model. J Androl 2003;24:381-387.
8. Zhang XH, Morelli A, Luconi M, et al. Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum. Eur Urol 2005;47:409-416; discussion 416. http://dx.doi.org/10.1016/j.eururo.2004.10.021
9. Shen ZJ, Zhou XL, Lu YL, et al. Effect of androgen deprivation on penile ultrastructure. Asian J Androl 2003;5:33-36.
10. Rogers RS, Graziottin TM, Lin CS, et al. Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-associated virus-mediated VEGF gene therapy prevent and reverse venogenic erectile dysfunction in rats. Int J Impot Res 2003;15:26-37. http://dx.doi.org/10.1038/sj.ijir.3900943
11. Traish AM, Park K, Dhir V, et al. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 1999;140:1861-1868. http://dx.doi.org/10.1210/en.140.4.1861
12. Shabsigh R, Rajfer J, Aversa A, et al. The evolving role of testosterone in the treatment of erectile dysfunction. Int J Clin Pract 2006;60:1087-1092. http://dx.doi.org/10.1111/j.1742-1241.2006.01101.x
13. Aversa A, Isidori AM, De Martino MU, et al. Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clin Endocrinol (Oxf) 2000;53:517-522. http://dx.doi.org/10.1046/j.1365-2265.2000.01118.x
14. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006;91:1995-2010. http://dx.doi.org/10.1210/jc.2005-2847
15. Isidori AM, Giannetta E, Gianfrilli D, et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf) 2005;63:381-394. http://dx.doi.org/10.1111/j.1365-2265.2005.02350.x
16. Aversa A, Isidori AM, Spera G, et al. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 2003;58:632-638. http://dx.doi.org/10.1046/j.1365-2265.2003.01764.x
17. Buvat J, Montorsi F, Maggi M, et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med 2011;8:284-93. http://dx.doi.org/10.1111/j.1743-6109.2010.01956.x
18. Shabsigh R, Kaufman JM, Steidle C, et al. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004;172:658-663. http://dx.doi.org/10.1097/01.ju.0000132389.97804.d7
19. Greco EA, Spera G, Aversa A. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences. Eur Urol 2006;50:940-947. http://dx.doi.org/10.1016/j.eururo.2006.06.049
20. Chatterjee R, Wood S, McGarrigle HH, et al. A novel therapy with testosterone and sildenafil for erectile dysfunction in patients on renal dialysis or after renal transplantation. J Fam Plann Reprod Health Care 2004;30:88-90. http://dx.doi.org/10.1783/147118904322995438
21. Greenstein A, Mabjeesh NJ, Sofer M, et al. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? J Urol 2005;173:530-532. http://dx.doi.org/10.1097/01.ju.0000149870.36577.05
22. Hwang TI, Chen HE, Tsai TF, et al. Combined use of androgen and sildenafil for hypogonadal patients unresponsive to sildenafil alone. Int J Impot Res 2006;18:400-404. http://dx.doi.org/10.1038/sj.ijir.3901446
23. Rosenthal BD, May NR, Metro MJ, et al. Adjunctive use of AndroGel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone. Urology 2006;67:571-574. http://dx.doi.org/10.1016/j.urology.2005.09.032
24. Yassin AA, Saad F, Diede HE. Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled study. Andrologia 2006;38:61-68. http://dx.doi.org/10.1111/j.1439-0272.2006.00712.x
25. Tsertsvadze A, Fink HA, Yazdi F, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med 2009;151:650-661.
26. Chatterjee R, Kottaridis PD, McGarrigle HH, et al. Management of erectile dysfunction by combination therapy with testosterone and sildenafil in recipients of high-dose therapy for haematological malignancies. Bone Marrow Transplant 2002;29:607-610. http://dx.doi.org/10.1038/sj.bmt.1703421
27. Foresta C, Caretta N, Rossato M, et al. Role of androgens in erectile function. J Urol 2004;171:2358-2362, quiz 2435. http://dx.doi.org/10.1097/01.ju.0000124323.02868.68
28. Rochira V, Balestrieri A, Madeo B, et al. Sildenafil improves sleep-related erections in hypogonadal men: evidence from a randomized, placebo-controlled, crossover study of a synergic role for both testosterone and sildenafil on penile erections. J Androl 2006;27:165-175. http://dx.doi.org/10.2164/jandrol.05077
29. Shamloul R, Ghanem H, Fahmy I, et al. Testosterone therapy can enhance erectile function response to sildenafil in patients with PADAM: a pilot study. J Sex Med 2005;2:559-564. http://dx.doi.org/10.1111/j.1743-6109.2005.00071.x
30. Kalinchenko, S. Y., Kozlov, G. I., Gontcharov, N. P., & Katsiya, G. V. (2003). Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male, 6(2), 94-99.
31. Tas A, Ersoy A, Ersoy C, et al. Efficacy of sildenafil in male dialysis patients with erectile dysfunction unresponsive to erythropoietin and/or testosterone treatments. Int J Impot Res 2006;18:61-68. http://dx.doi.org/10.1038/sj.ijir.3901372
32. Salonia A, Rigatti P, Montorsi F. Sildenafil in erectile dysfunction: a critical review. Curr Med Res Opin 2003;19:241-262. http://dx.doi.org/10.1185/030079903125001839
33. Guay AT, Perez JB, Jacobson J, et al. Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J Androl 2001;22:793-797.
34. Seftel AD, Mack RJ, Secrest AR, et al. Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. J Androl 2004;25:963-972.
35. Chiang HS, Hwang TI, Hsui YS, et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. Int J Impot Res 2007;19:411-417. http://dx.doi.org/10.1038/sj.ijir.3901562
36. Traish AM, Goldstein I, Kim NN. Testosterone and erectile function: from basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction. Eur Urol 2007;52:54-70. http://dx.doi.org/10.1016/j.eururo.2007.02.034
37. Aversa A, Isidori AM, Greco EA, et al. Hormonal supplementation and erectile dysfunction. Eur Urol 2004;45:535-538. http://dx.doi.org/10.1016/j.eururo.2004.01.005
38. Buvat J, Bou Jaoude G. Significance of hypogonadism in erectile dysfunction. World J Urol 2006;24:657-67. http://dx.doi.org/10.1007/s00345-006-0131-x
39. Jaoudé, J. B. A. G. B. (2008). Combination therapy with phosphodiesterase type V inhibitors and testosterone Current Sexual Health Reports, 5(3), 135-140.
40. Nieschlag E, Swerdloff R, Behre HM, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. Eur Urol 2005;48:1-4. http://dx.doi.org/10.1016/j.eururo.2005.04.027
41. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 2008;159:507-514. http://dx.doi.org/10.1530/EJE-08-0601